Verastem, Inc. (NASDAQ:VSTM) is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation. The company’s current product line includes: FAK, PI3K/mTOR and Wnt. Verastem’s proprietary research has developed a system for the discovery of a new generation of cancer drugs that can selectively target CSCs and provide a strategy for treatment of cancer patients. By engineering tumor cells to stably transition to CSCs, Verastem has established high-throughput drug discovery systems that make it possible to identify and develop drugs specifically targeting CSCs. For more information, visit the company’s website at www.verastem.com